T M Grogan
Overview
Explore the profile of T M Grogan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
2744
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rybski J, Spier C, Miller T, Lippman S, McGee D, Grogan T
Leuk Lymphoma
. 2016 Jul;
6(1):31-8.
PMID: 27457573
Ninety-nine consecutive diffuse large cell lymphoma (DLCL) patients were studied by immunohistochemistry to determine whether clinical outcome was predicted by major histocompatibility complex (MHC) antigen phenotypic expression. Statistically significantly shorter...
2.
Mimae T, Tsuta K, Kondo T, Nitta H, Grogan T, Okada M, et al.
Ann Oncol
. 2012 Jun;
23(12):3129-3137.
PMID: 22700994
Background: Insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-type 2 (HER2), and c-Met are members of the receptor tyrosine kinases (RTKs). The associations...
3.
Pileri S, Grogan T, Harris N, Banks P, Campo E, Chan J, et al.
Histopathology
. 2002 Jul;
41(1):1-29.
PMID: 12121233
Neoplasms of histiocytes and dendritic cells are rare, and their phenotypic and biological definition is incomplete. Seeking to identify antigens detectable in paraffin-embedded sections that might allow a more complete,...
4.
Press O, LeBlanc M, Lichter A, Grogan T, Unger J, Wasserman T, et al.
J Clin Oncol
. 2001 Nov;
19(22):4238-44.
PMID: 11709567
Purpose: The management of early-stage Hodgkin's disease in the United States is controversial. To evaluate whether staging laparotomy could be safely avoided in early-stage Hodgkin's disease and whether chemotherapy should...
5.
Fracasso P, Brady M, Moore D, Walker J, Rose P, Letvak L, et al.
J Clin Oncol
. 2001 Jun;
19(12):2975-82.
PMID: 11408492
Purpose: A phase II study was conducted to determine the efficacy of paclitaxel and valspodar (PSC 833) in patients with advanced epithelial ovarian cancer. Valspodar, a nonimmunosuppressive cyclosporine D analogue...
6.
Braziel R, Arber D, Slovak M, Gulley M, Spier C, Kjeldsberg C, et al.
Blood
. 2001 Jun;
97(12):3713-20.
PMID: 11389007
The Revised European-American Lymphoma classification gives Burkitt-like lymphoma (BLL) provisional status, leaving unresolved the differential diagnosis with Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). This study compared the...
7.
Tubbs R, Pettay J, Roche P, Stoler M, Jenkins R, Grogan T
J Clin Oncol
. 2001 May;
19(10):2714-21.
PMID: 11352964
Background: Several studies have reported what seem to be false-positive results using the Food and Drug Administration (FDA)-approved HercepTest (Dako Corp, Carpinteria, CA) to profile Her-2/neu amplification and overproduction in...
8.
Bellamy W, Richter L, Sirjani D, Roxas C, Frutiger Y, Grogan T, et al.
Blood
. 2001 Feb;
97(5):1427-34.
PMID: 11222390
Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide with biologic effects that include regulation of hematopoietic stem cell development, extracellular matrix remodeling, and inflammatory cytokine generation. To delineate...
9.
Gaynor E, Unger J, Miller T, Grogan T, White Jr L, Mills G, et al.
J Clin Oncol
. 2001 Feb;
19(3):750-5.
PMID: 11157027
Purpose: Two phase II studies were conducted to evaluate infusional cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy, termed the CVAD regimen, alone (Southwest Oncology Group [SWOG] 9240) and with the chemosensitizers...
10.
Stopeck A, Gessner A, Miller T, Hersh E, Johnson C, Cui H, et al.
Clin Cancer Res
. 2000 Oct;
6(10):3904-9.
PMID: 11051236
Tumor-infiltrating CD8+ T-lymphocytes (T-TILs) are thought to be relevant to immunosurveillance of several tumor types including B-cell non-Hodgkin's lymphoma. B- and T-lymphocyte interactions via cellular adhesion molecules (CAMs), recognition molecules...